Caffarelli Anthony D, Holden Jeff P, Baron Ellen Jo, Lemmens Harry J M, D'Souza Holly, Yau Vincent, Olcott Cornelius, Reitz Bruce A, Miller D Craig, van der Starre Pieter J A
Department of Cardiothoracic Surgery, Stanford University, Stanford, Calif, USA.
J Thorac Cardiovasc Surg. 2006 Jun;131(6):1338-43. doi: 10.1016/j.jtcvs.2005.11.047.
We sought to assess the effects of cardiopulmonary bypass and profound hypothermic circulatory arrest on plasma cefazolin levels administered for antimicrobial prophylaxis in cardiovascular surgery.
Four groups (10 patients per group) were prospectively studied: vascular surgery without cardiopulmonary bypass (group A), cardiac surgery with a cardiopulmonary bypass time of less than 120 minutes (group B), cardiac surgery with a cardiopulmonary bypass time of greater than 120 minutes (group C), and cardiac surgery with cardiopulmonary bypass and profound hypothermic circulatory arrest (group D). Subjects received cefazolin at induction and a second dose before wound closure. Arterial blood samples were obtained preceding cefazolin administration, at skin incision, hourly during the operation, and before redosing. Cefazolin plasma concentrations were determined by using a radial diffusion assay, with Staphylococcus aureus as the indicator microorganism. Cefazolin plasma concentrations were considered noninhibitory at 8 microg/mL or less, intermediate at 16 mug/mL, and inhibitory at 32 microg/mL or greater.
In group A cefazolin plasma concentrations remained greater than 16 microg/mL during the complete surgical procedure. In group B cefazolin plasma concentrations diminished to 16 microg/mL or less in 30% of the patients but remained greater than 8 microg/mL. In group C cefazolin plasma concentrations decreased to less than 16 microg/mL in 60% of patients and were less than 8 microg/mL in 50% of patients. In group D cefazolin plasma concentrations reached 16 microg/mL in 66% of the patients but decreased to 8 microg/mL in only 1 patient.
For patients undergoing cardiac surgery with a cardiopulmonary bypass time of greater than 120 minutes, a single dose of cefazolin before skin incision with redosing at wound closure does not provide targeted antimicrobial cefazolin plasma levels during the entire surgical procedure. Patients undergoing profound hypothermic circulatory arrest are better protected, but the described protocol of prophylaxis is not optimal.
我们试图评估心肺转流术和深度低温循环停搏对心血管手术中用于抗菌预防的血浆头孢唑啉水平的影响。
前瞻性研究四组(每组10例患者):非心肺转流术的血管手术(A组)、心肺转流时间小于120分钟的心脏手术(B组)、心肺转流时间大于120分钟的心脏手术(C组)以及心肺转流和深度低温循环停搏的心脏手术(D组)。受试者在诱导时接受头孢唑啉,并在伤口闭合前给予第二剂。在头孢唑啉给药前、皮肤切开时、手术期间每小时以及再次给药前采集动脉血样。使用以金黄色葡萄球菌为指示微生物的放射扩散测定法测定头孢唑啉血浆浓度。头孢唑啉血浆浓度在8微克/毫升或更低时被认为无抑制作用,在16微克/毫升时为中等抑制作用,在32微克/毫升或更高时为有抑制作用。
在A组中,整个手术过程中头孢唑啉血浆浓度保持大于16微克/毫升。在B组中,30%的患者头孢唑啉血浆浓度降至16微克/毫升或更低,但仍大于8微克/毫升。在C组中,60%的患者头孢唑啉血浆浓度降至低于16微克/毫升,50%的患者低于8微克/毫升。在D组中,66%的患者头孢唑啉血浆浓度达到16微克/毫升,但仅1例患者降至8微克/毫升。
对于心肺转流时间大于120分钟的心脏手术患者,皮肤切开前单剂量头孢唑啉并在伤口闭合时再次给药不能在整个手术过程中提供靶向抗菌的头孢唑啉血浆水平。接受深度低温循环停搏的患者得到了更好的保护,但所描述的预防方案并非最佳。